These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

279 related items for PubMed ID: 10519421

  • 1. A soluble transforming growth factor beta type III receptor suppresses tumorigenicity and metastasis of human breast cancer MDA-MB-231 cells.
    Bandyopadhyay A, Zhu Y, Cibull ML, Bao L, Chen C, Sun L.
    Cancer Res; 1999 Oct 01; 59(19):5041-6. PubMed ID: 10519421
    [Abstract] [Full Text] [Related]

  • 2. Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects.
    Tobin SW, Douville K, Benbow U, Brinckerhoff CE, Memoli VA, Arrick BA.
    Oncogene; 2002 Jan 03; 21(1):108-18. PubMed ID: 11791181
    [Abstract] [Full Text] [Related]

  • 3. Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells.
    Ye SC, Foster JM, Li W, Liang J, Zborowska E, Venkateswarlu S, Gong J, Brattain MG, Willson JK.
    Cancer Res; 1999 Sep 15; 59(18):4725-31. PubMed ID: 10493532
    [Abstract] [Full Text] [Related]

  • 4. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
    Arteaga CL, Hurd SD, Winnier AR, Johnson MD, Fendly BM, Forbes JT.
    J Clin Invest; 1993 Dec 15; 92(6):2569-76. PubMed ID: 7504687
    [Abstract] [Full Text] [Related]

  • 5. Extracellular domain of TGFbeta type III receptor inhibits angiogenesis and tumor growth in human cancer cells.
    Bandyopadhyay A, Zhu Y, Malik SN, Kreisberg J, Brattain MG, Sprague EA, Luo J, López-Casillas F, Sun LZ.
    Oncogene; 2002 May 16; 21(22):3541-51. PubMed ID: 12032856
    [Abstract] [Full Text] [Related]

  • 6. Deletion of one adenine base within the polyadenine tract of transforming growth factor-beta receptor type II in human MDA-MB-231 breast cancer cell line.
    Park B, Jang JS, Park K.
    Int J Oncol; 2000 Sep 16; 17(3):473-8. PubMed ID: 10938386
    [Abstract] [Full Text] [Related]

  • 7. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F, Lee J, Lu S, Pettaway CA, Dong Z.
    Clin Cancer Res; 2005 Jun 15; 11(12):4512-20. PubMed ID: 15958637
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Antitumor activity of a recombinant soluble betaglycan in human breast cancer xenograft.
    Bandyopadhyay A, López-Casillas F, Malik SN, Montiel JL, Mendoza V, Yang J, Sun LZ.
    Cancer Res; 2002 Aug 15; 62(16):4690-5. PubMed ID: 12183427
    [Abstract] [Full Text] [Related]

  • 10. Expression of transforming growth factor-beta receptor type II and tumorigenicity in human breast adenocarcinoma MCF-7 cells.
    Ko Y, Banerji SS, Liu Y, Li W, Liang J, Soule HD, Pauley RJ, Willson JK, Zborowska E, Brattain MG.
    J Cell Physiol; 1998 Aug 15; 176(2):424-34. PubMed ID: 9648930
    [Abstract] [Full Text] [Related]

  • 11. Restoration of transforming growth factor-beta type II receptor reduces tumorigenicity in the human adrenocortical carcinoma SW-13 cell line.
    Yamamoto N, Imai J, Watanabe M, Hiroi N, Sugano S, Yoshino G.
    Horm Metab Res; 2006 Mar 15; 38(3):159-66. PubMed ID: 16673206
    [Abstract] [Full Text] [Related]

  • 12. Transforming growth factor-beta1 is the predominant isoform required for breast cancer cell outgrowth in bone.
    Mourskaia AA, Dong Z, Ng S, Banville M, Zwaagstra JC, O'Connor-McCourt MD, Siegel PM.
    Oncogene; 2009 Feb 19; 28(7):1005-15. PubMed ID: 19079339
    [Abstract] [Full Text] [Related]

  • 13. Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation.
    Rowland-Goldsmith MA, Maruyama H, Kusama T, Ralli S, Korc M.
    Clin Cancer Res; 2001 Sep 19; 7(9):2931-40. PubMed ID: 11555612
    [Abstract] [Full Text] [Related]

  • 14. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
    Moore LD, Isayeva T, Siegal GP, Ponnazhagan S.
    Clin Cancer Res; 2008 Aug 01; 14(15):4961-70. PubMed ID: 18676771
    [Abstract] [Full Text] [Related]

  • 15. Overexpression of transforming growth factor beta type I receptor abolishes malignant phenotype of a rat bladder carcinoma cell line.
    Okamoto M, Oyasu R.
    Cell Growth Differ; 1997 Aug 01; 8(8):921-6. PubMed ID: 9269901
    [Abstract] [Full Text] [Related]

  • 16. Autocrine TGFbeta supports growth and survival of human breast cancer MDA-MB-231 cells.
    Lei X, Bandyopadhyay A, Le T, Sun L.
    Oncogene; 2002 Oct 24; 21(49):7514-23. PubMed ID: 12386814
    [Abstract] [Full Text] [Related]

  • 17. TGF-beta promotes the establishment of renal cell carcinoma bone metastasis.
    Kominsky SL, Doucet M, Brady K, Weber KL.
    J Bone Miner Res; 2007 Jan 24; 22(1):37-44. PubMed ID: 17032147
    [Abstract] [Full Text] [Related]

  • 18. Smad-binding defective mutant of transforming growth factor beta type I receptor enhances tumorigenesis but suppresses metastasis of breast cancer cell lines.
    Tian F, Byfield SD, Parks WT, Stuelten CH, Nemani D, Zhang YE, Roberts AB.
    Cancer Res; 2004 Jul 01; 64(13):4523-30. PubMed ID: 15231662
    [Abstract] [Full Text] [Related]

  • 19. Over-expression of ERT(ESX/ESE-1/ELF3), an ets-related transcription factor, induces endogenous TGF-beta type II receptor expression and restores the TGF-beta signaling pathway in Hs578t human breast cancer cells.
    Chang J, Lee C, Hahm KB, Yi Y, Choi SG, Kim SJ.
    Oncogene; 2000 Jan 06; 19(1):151-4. PubMed ID: 10644990
    [Abstract] [Full Text] [Related]

  • 20. Loss of responsiveness to transforming growth factor beta induces malignant transformation of nontumorigenic rat prostate epithelial cells.
    Tang B, de Castro K, Barnes HE, Parks WT, Stewart L, Böttinger EP, Danielpour D, Wakefield LM.
    Cancer Res; 1999 Oct 01; 59(19):4834-42. PubMed ID: 10519393
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.